Patent 11254670 was granted and assigned to Nuvation Bio on February, 2022 by the United States Patent and Trademark Office.
1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.